Germany’s Innovation Paradox

In 1990, a group of brilliant engineers set out to build the future. They envisioned mobile and cloud computing, digital assistants, connected devices, mobile commerce, and software ecosystems. Their company was called General Magic. General Magic did not lack talent, vision, funding, or prestigious backers. It failed because the ecosystem and infrastructure were not ready, its business model had not been validated with customers, and execution could not turn the vision into a scalable consumer product.

Its story has long fascinated me because it challenges a common misconception: innovation is not invention, patents, or technology alone. Innovation is the ability to turn ideas into outcomes. That requires timing, customer adoption, a viable business model, and an ecosystem capable of delivering at scale.

When I look at Germany, I see a similar risk. Not because Germany lacks innovation, but because it someƟmes struggles to scale it.

Germany’s Innovation Paradox

Over recent months, I have repeatedly been asked: “Why is Germany not innovative anymore?” I believe the quesƟon is wrong. Germany remains a leading innovator, investing more than 3% of GDP in research and development. Its companies, universities, and institutes continue to produce world-class science, engineering, patents, and industrial innovation. Fraunhofer, Max Planck, Bosch, Siemens, SAP, Zeiss, BioNTech, BIOTRONIK, and many hidden champions prove the depth of that capability. Talent and research are not the problem.

Yet uncomfortable quesƟons remain. Why did frontier AI leadership emerge elsewhere? Why are the dominant cloud platforms mostly American? Why did Germany pioneer solar technology while manufacturing shifted to Asia? Why has autonomous driving leadership moved toward the United States and China?

Germany’s central challenge is not invention. It is the gap between technological excellence and scalable impact, between building something valuable and capturing the value it creates.

That distinction matters because innovation idea and innovation impact are not the same. A country can lead in research spending, patents, and prototypes while others lead in platforms, markets, and value capture.

The Difference Between Building Infrastructure and Building Futures

Healthcare makes this paradox especially visible. For more than two decades, Germany has built the Telematics Infrastructure, eRezept, electronic patient records, secure communication channels, and trusted digital identities. Connecting physicians, pharmacies, hospitals, insurers, regulators, soŌware providers, and millions of patients in a regulated system required extraordinary coordination.

Germany ultimately succeeded. eRezept is now the standard prescription mechanism, and the electronic patient record is reaching more than 70 million people covered by statutory health insurance.

But success came with years of delays, redesigns, major investments, and operational complexity. A data and software challenge was often approached through an infrastructure-centric lens, with specialized hardware and multiple layers of certification. Many decisions were understandable because trust maƩers deeply in healthcare, but the architecture became expensive to operate and
difficult to change.

The question is no longer whether Germany can digitize healthcare. It is what value we now build on top of that infrastructure. Digitizing paper is not transformation. Access, storage, interoperability, privacy, and cybersecurity remain essential. Yet they are enabling starting points. The strategic questions concern outcomes: what decisions will improve, which workflows will change, and how patients, professionals, and researchers will benefit.

A Learning Health System uses data not only to document what happened, but to improve what happens next. Patient data generates evidence, evidence improves treatment, and treatment creates new data. We call this an AI flywheel.

From Products to Ecosystems

I learned this firsthand in healthcare. My teams and I worked on heart-failure prediction models that could identify elevated patient risks earlier than traditional approaches. The algorithm was impressive, but value emerged only when data, clinical workflows, physicians, medical devices, and patient outcomes became connected.

This is why an AI pilot can appear successful while the organization around it remains unchanged. Accuracy is necessary, but adoption, workflow integration, accountability, and measurable outcome determine whether an innovation survives beyond the demonstration.

The same principle applies beyond healthcare. Apple did not scale through a smartphone alone, nor Amazon through online retail alone. They built ecosystems in which partners and customers could create additional value.

Germany has invested heavily in foundations. Now it must turn platforms into ecosystems and infrastructure into measurable outcomes. The Telematics Infrastructure is an enabling architecture, not the final product.

Following the Money

Innovation requires ideas. Scaling requires capital. Germany has made progress through EXIST, High-Tech Gründerfonds, KfW initiatives, European or regional programs, and corporate venture capital.

Public funding supports long-term research and reduces risk, but founders often spend too much time navigating eligibility, applications, reporting, and fragmented sources. The larger gap appears during growth, when companies need patient, risk-tolerant capital to iterate, survive setbacks, expand internationally, and scale before the window closes.

Germany is improving at creating start-ups. The harder task is creating global technology champions. The future is often determined not by who invents first, but by who scales fastest.

The quality of capital also matters. Growth investors must bring market access, operational expertise, and the patience to support several learning cycles, while public institutions should simplify access and use procurement more deliberately to create early reference customers.

This will avoid what is called a “flip”: creating a start-up in Europe and then move it to US to increase access to capital and accelerate scale-up.

Innovation at an Early Stage

Germany may also have an innovation-accounting problem. Mature businesses are measured through budgets, milestones, reliability, and delivery. Early-stage innovation operates under uncertainty, so its first objective must be learning through fast prototypes and experiments.

When emerging initiatives are judged by mature-business metrics, organizations reward activity rather than evidence. Patents, projects, and infrastructure matter, but markets reward adoption, ecosystems, and customer value. Leaders must measure how quickly assumptions (technical, business, customer, market etc.) are tested, what is learned, and whether evidence justifies the next investment.

This requires portfolio discipline. Some initiatives should be stopped quickly, others accelerated, and resources moved as evidence changes. Protecting every project is not innovation management. It is avoidance of choice.

The Failure Problem

Germany’s expertise, planning, precision, and reliability are genuine strengths, especially in healthcare, aerospace, industrial manufacturing, and critical infrastructure. They help us build cathedrals that endure.

Innovation, however, requires experimentation, and experiments often fail. If failure is treated only as poor judgment, people learn to avoid mistakes rather than discover what works.

This should not mean accepting weak execution or lack of perseverance. It means distinguishing an intelligent experiment that produces evidence from repeated failure without learning. Psychological safety and accountability must reinforce each other.

General Magic failed, but its learning survived. Former employees helped create the iPod, iPhone, Android, eBay, and other successes. Germany should keep its cathedral-building strengths while adopting a Lego-style aƫtude: build, test, adapt, learn, and scale.

Reasons for Optimism

There are strong signals of what is possible. BioNTech created globally transformative medical innovation. DeepL built a leading European language AI platform. Celonis made process mining a global software category, while Infineon became a backbone of the energy transition through power semiconductors.

Three further companies broaden the picture. Isar Aerospace is developing sovereign European access to space and became the first commercial company to launch an orbital rocket from continental Europe. Agile Robots combines AI and robotics to bring physical AI into industrial operations. Helsing is building AI-enabled defense systems and shows that Europe can create strategically important technology companies in a demanding, regulated domain.

These companies operate in very different markets, but none can scale through technology alone. They need capital, customers, partners, infrastructure, talent, regulation, and execution to move together.

Implications for Executives

From my years of experience leading technology, product, AI, and digital transformations: scaling innovation must become an executive and board responsibility.

Boards need a coherent strategy in which innovation is not a side initiative, but a central driver of growth. This includes quantifying how innovation and new digital business models will contribute to future revenues, customer value, and competitive advantage.

Boards and executives must also become literate in technology, data, and AI, particularly as these capabilities are increasingly insourced and become part of the company’s core competence. This requires programmatic upskilling across the complete organization, with dedicated development programs covering data centricity, AI, cloud, and digital business models.

Building a data and AI-driven organization requires more than experimenting with GenAI. Without clear ownership, governance, and data platforms, experiments remain experiments. Leaders should redesign organization and complete workflows around data and AI, rather than inserting AI into a single process step.

Executives should separate exploration from execution. For early-stage innovation apply learning metrics before financial metrics, and release funding in stages as evidence grows. Innovation portfolios need explicit decisions to continue, pivot, scale, or stop (based on value creation, time criticality, cost, risk reduction, and opportunity potential).

Regulation, cybersecurity, quality, and privacy should be treated as by-design that build trust.

Most importantly, agility must extend across the entire value chain. It is not enough for research and development to work differently if sales, operations, partners, and governance continue at another speed.

This requires a culture that combines psychological safety with radical accountability.

Conclusion

General Magic saw much of the future correctly, but being right was not enough. The value was captured by those who combined vision with timing, technology with ecosystems, and innovation with scale.

Germany already has the ideas, talent, engineering excellence, industrial base, and commitment to trust. Its opportunity is to convert these strengths into adoption and global impact without losing what makes German innovation valuable.

History rarely remembers who imagined the future first. It remembers who made it real.

What must executives change now so that Germany’s next breakthrough is not only invented here, but scaled from here?

Mihai Diga is an international technology C-level executive, board member, and AI transformation leader with more than 25 years of experience in healthcare, MedTech, and other regulated industries.

Building on senior roles at Phoenix Pharma, Fresenius Medical Care, and Biotronik, he has led digital, AI, and business transformations globally, helping organizations turn innovation into measurable business value through strategy, governance, technology, and organizational culture.